EOF方案术前动脉介入化疗对胃癌患者血糖影响的回顾性研究-东南大学学报医学版

EOF方案术前动脉介入化疗对胃癌患者血糖影响的回顾性研究

单位：江苏省中医院消化肿瘤外科, 江苏南京 210029

分类号：R735.2

出版年·卷·期（页码）：2015·34·第五期（779-782）

摘要：

目的:探讨胃癌患者接受EOF方案术前动脉介入化疗前后血糖水平的变化,并分析相关因素对血糖变化的影响。方法:收集2012年至2014年间92例接受EOF方案术前动脉介入化疗的胃癌患者在介入化疗前及介入化疗后24 h的空腹血糖检验结果及相关临床资料,进行回顾性分析。结果:EOF方案动脉介入化疗后患者血糖平均水平增加,与介入化疗前相比差异有统计学意义(P<0.01)。患者年龄、性别、肿瘤部位、肿瘤分期等相关因素对血糖升高的影响差异无统计学意义(P>0.05)。合并糖尿病的胃癌患者动脉介入化疗后血糖升高水平明显高于非糖尿病患者,差异有统计学意义(P<0.001)。结论:EOF方案动脉介入化疗可使胃癌患者的血糖升高,尤其是合并糖尿病的胃癌患者血糖升高尤为明显,在积极治疗原发病的同时应注意监测患者血糖并及时处理。

Objective: To explore the effects of the preoperative intra-arterial infusion chemotherapy(PAIC) with EOF regimen on blood glucose of gastric cancer patients and to find the influencing factors. Methods: 92 patients with gastric cancer participated in the study; they had received PAIC from 2012 to 2014 in our hospital.The regimen consisted of EPI 50 mg·m^-2,OXA 130 mg·m^-2,and 5-FU 750 mg·m^-2.Their blood glucose was detected on schedule before and after chemotherapy; clinical factors were collected.Some changed regularity on blood glucose and the influential factors were found after chemotherapy. Results: After PAIC, patients' blood glucose was higher than before the treatment(P<0.01).Age, gender, tumor location and tumor stage had no obvious impact on blood glucose changes before and after PAIC(P>0.05).Gastric cancer patients with diabetes were more vulnerable to induce blood glucose rose after PAIC(P<0.001).Conclusion: PAIC could enhance blood glucose level in gastric cancer patients, especially in patients with diabetes mellitus. In order to complete tumor chemotherapy safely and successfully, strict monitoring of blood glucose and appropriate measures to control high blood sugar should be taken.

参考文献：

[1] 周亮,姚学权,陈彻,等.进展期胃癌患者行术前动脉介入化疗对肝脏微环境的影响[J].东南大学学报:医学版,2013,32(6):669-673.
[2] 李东,吴萍山.术前动脉介入化疗治疗进展期胃癌的病例对照研究[J].中国癌症杂志,2010,20(4):290-294.
[3] 吴鹏,朱正纲,叶正宝,等.5-氟脲嘧啶-2,-脱氧核苷经胃左动脉介入灌注化疗的药代动力学实验研究[J].外科理论与实践,2004,9(2):135-139.
[4] DISPENZIERI A,LOPRINZI C L.Chemotherapy-induced insulin-dependent diabetes mellitus[J].J Clin Oncol,1997,15(3):1287.
[5] NGUYEN N P,VOS P,VINH-HUNG V,et al.Altered glucose metabolism during chemoradiation for head and neck cancer[J].Anticancer Res,2009,29(11):4683-4687.
[6] 陆再英,钟南山.内科学.7版.北京:人民卫生出版社,2008:770-793.
[7] WARBURG O,WIND F,NEGELEIN E.The metabolism of tumors in the body[J].J Gen Physiol,1927,8(6):519-530.
[8] CHANG C K,ULRICH C M.Hyperinsulinaemia and hyperglycaemia:possible risk factors of colorectal cancer among diabetic patients[J].Diabetologia,2003,46(5):595-607.
[9] ZHOU J,HUANG W,TAO R,et al.Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells[J].Oncogene,2009,28(18):1993-2002.
[10] GOLDSTEIN R S,MAYOR G H,GINGERICH R L,et al.The effects of cisplatin and other divalent platinum compounds on glucose metabolism and pancreatic endocrine function[J].Toxicol Appl Pharmacol,1983,69(3):432-441.
[11] 冯觉平,陈继贵,袁响林,等.氟尿嘧啶对大鼠血糖代谢及胰腺病理结构的影响[J].中华胃肠外科杂志,2010,13(12):935-938.
[12] 冯觉平,方静,袁响林,等.5-氟尿嘧啶为基础的联合化疗对结直肠癌患者血糖代谢的影响[J].肿瘤,2010,30(10):865-869.
[13] 陈勇,关丽云,冯莉,等.含奥沙利铂联合方案引起肝功能异常的临床分析[J].肿瘤研究与临床,2009(5):332-334.
[14] 陈居敏,贾玲,吴迪,等.乳腺癌化疗过程中血糖异常升高的临床分析[J].中国实用医药,2009,4(8):121-122.
[15] NAN D N,FERNNDEZ-AYALA M,VEGA-VILLEGAS M E,et al.Diabetes mellitus following cisplatin treatment[J].Acta Oncol,2003,42(1):75-78.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录